Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy’s Laboratories, Sun Pharma, Lupin and Zydus Lifesciences, noted that Trump’s latest tariff will not have implications for the generic drugmakers.
